CN106924337A - Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease - Google Patents
Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease Download PDFInfo
- Publication number
- CN106924337A CN106924337A CN201710236683.4A CN201710236683A CN106924337A CN 106924337 A CN106924337 A CN 106924337A CN 201710236683 A CN201710236683 A CN 201710236683A CN 106924337 A CN106924337 A CN 106924337A
- Authority
- CN
- China
- Prior art keywords
- ash
- bark
- yellow
- yellow bark
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Abstract
The invention discloses application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease, during present invention application Huang bark of ash treatment livestock and poultry virus sexually transmitted disease, curative effect is high, Small side effects, for clinical treatment livestock and poultry virus sexually transmitted disease provides a kind of new selection.
Description
Technical field
The invention belongs to the field of Chinese medicines, and in particular to yellow bark of ash and its extract are preparing treatment livestock and poultry virus sexually transmitted disease
Medicine in application.
Background technology
The fashion trend of current livestock and poultry virus sexually transmitted disease is increasingly serious, falls ill wide, propagates fast, spreads rapidly, so that
Cause the loss of aquaculture quite serious.And in livestock and poultry infectious disease, the large percentage that viral infectious are accounted for, many plants exist
In the case of not determining cause of disease, health care and treatment are come using antibiotic or sulfa drugs.For viral infectious, antibiosis
Element, sulfa drugs are without therapeutic action, also many side effects.Although Western medicine such as amantadine, Ribavirin, ACVs,
With certain curative effect, but effect is not ideal, the defect that also antiviral spectrum is narrow, toxic and side effect is big.Oseltamivir phosphate (reaches
It is luxuriant and rich with fragrance) antiviral effect is good but expensive, and livestock and poultry can not use, and be also easy to produce resistance strain.Therefore, novel antiviral is sought
Medicine is extremely urgent.
Yellow bark of ash be called the Yunnan root of large-flowered skullcap, Lijing it is invaluable, it is big it is bitter as, gentian, yellow bark of ash Veratrila
BaillaniiFranch is the root of gentianaceae plant Huang bark of ash.Sichuan, Yunnan mainly are originated in, height above sea level 3000- is born in Tibet
In 4600 meters of alpine meadow, shrubbery.With various pharmacological activity such as heat-clearing, anti-inflammatory, removing toxic substances, desinsection.
So far, there is not yet yellow bark of ash prevents and treats the report of livestock and poultry virus sexually transmitted disease.
The content of the invention：
The present invention is few for the medicine for the treatment of livestock and poultry virus sexually transmitted disease at present, and the antiviral Western medicine of people, animal is to prohibit
, and effect is also bad, the big problem of side effect, there is provided and yellow bark of ash is preparing the medicine for the treatment of livestock and poultry virus sexually transmitted disease
In application.
The purpose of the present invention is implemented by the following technical programs：
Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease.Described livestock and poultry virus sexually transmitted disease
It is newcastle disease or pig virus infectious disease, pig virus infectious disease can be Porcine circovirus desease, swine fever or swine fever and pig annulus
Virus mixed infection.Foregoing yellow bark of ash refers not only to yellow bark of ash raw medicinal herbs in itself, is also extracted including yellow bark of ash processed product, yellow bark of ash
Thing, preparation with yellow bark of ash as active component or the preparation one of with yellow bark of ash as active component；Preferably yellow Radix Gentianae Macrophyllae extract
Or the preparation with yellow bark of ash as active component.
Huang Radix Gentianae Macrophyllae extract of the invention is as solvent, using carbon dioxide supercritical extraction using water or organic solvent
The extract of the routine techniques such as method, diacolation, decoction.Described organic solvent refers to the solvent of the opposed polarities such as ethanol, methyl alcohol.It is excellent
Choosing uses mass percent concentration for methyl alcohol that 70%~90% ethanol or mass percent concentration are 75%~85%.
Water extract is preferably prepared as follows and obtains：
Yellow bark of ash is taken, after being soaked by 5~20 times of medicinal material weight, is decocted 2~4 times, 1~3h, merges and decoct every time
Liquid, dehydration is concentrated into paste, drying Huang Radix Gentianae Macrophyllae extract.
Extractive with organic solvent is preferably prepared as follows and obtains：
Yellow bark of ash is taken, is crushed, by 70%~90% ethanol (mass percent concentration) of 5~20 times of weight of medicinal material weight
Or 75%~85% methyl alcohol (mass percent concentration) soak 1~4 hour after, diacolation, reclaim ethanol, be concentrated into paste, it is low
Warm decompression drying, obtains extract.
Yellow bark of ash raw medicinal herbs or its extract can directly be crushed and be made powder and use, or add pharmaceutically acceptable auxiliary
Material, oral formulations or injection are made using conventional method.The oral formulations are preferably mixture, tablet or oral liquid.
Medium domestic animal (such as pig, sheep) is every time 1~3g using yellow bark of ash primary crude drug, and 2 times a day, during poultry consumption is
Deng 1/10th of domestic animal.
Beneficial effects of the present invention：Inventor is with yellow bark of ash and its extract for treating newcastle disease, swine fever and pig circular ring virus 2
Malicious mixed infection, curative effect really stabilization.It is used to prepare the medicine for the treatment of livestock and poultry virus sexually transmitted disease the invention provides yellow bark of ash
In application, for clinical treatment livestock and poultry infectious disease provides a kind of new selection.
Specific embodiment：
Below by way of the specific embodiment of example forms, the above of the invention is remake further specifically
It is bright.But this scope for being interpreted as above-mentioned theme of the invention should not be only limitted to following example.It is all based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Curative effect of the invention is further illustrated with regard to clinical effectiveness of the invention below：
First, yellow bark of ash egg inoculation anti-new castle disease virus experiment.
1st, medicine：
(1) yellow bark of ash sample 1：Prepared according to the method for embodiment 1, every mL liquids crude drug containing 1g is made into physiological saline
Concentration.
(2) yellow bark of ash sample 2：Prepared according to the method for embodiment 2, every mL liquids crude drug containing 1g is made into physiological saline
Concentration.
(3) Chinese medicine control：Bark of ash parenteral solution, prepares according to the method for embodiment 12,
(4) Western medicine control：62.5mg/mL Acyclovir injections.
2nd, newcastle disease strain is provided by Jiangsu Agri-Animal Husbandry Vocational College laboratory, the HA potency of chick embryo allantoic liquid
9log2, after measured, minimum lethal dose is 1:30000000 times of dilutions.
3rd, the age in days of chicken embryo 10 is non-exempts from chicken embryo for experiment, purchased from the big instrument chicken house in Yizheng City.
4th, experiment packet instar chicken embryo 66 on the 10th, specific packet situation is shown in Table 1.
5th, test method
(1) yellow bark of ash sample 1 and yellow bark of ash sample 2 are used normal saline dilution by Drug toxicity trails respectively, by stoste and
The liquid of various concentrations is inoculated in 3 allantoic cavities of instar chicken embryo on the 10th respectively, and every 0.2mL puts 38 DEG C of incubation 72h,
Survival condition is observed daily, and the highest liquor strength that chicken embryo is all survived tests initial concentration for formal, while setting physiological saline
Control group, medicine is shown in Table 2 to embryonic toxicity experimental result.
The experiment packet situation of table 1
| Numbering | Group | Quantity (piece) | Treatment |
| 1 | Test 1 group | 11 | Yellow bark of ash sample 1 |
| 2 | Test 2 groups | 11 | Yellow bark of ash sample 2 |
| 3 | Test 3 groups | 11 | ACV |
| 4 | Chinese medicine is compareed | 11 | Bark of ash parenteral solution |
| 5 | Positive controls | 11 | Virus inoculation allantoic fluid, by tested number to physiological saline |
| 6 | Blank control group | 11 | Not virus inoculation allantoic fluid, be not administered |
The Chinese medicine of table 2 is to embryonic toxicity experimental result (n=4)
* denominator is inoculation embryo number, and molecule is survival embryo number.
(2) specific method：
Test 1 group of each chick embryo allantoic cavity and be inoculated with yellow bark of ash sample 1 stoste 0.2mL, viral dilution liquid 0.1mL simultaneously.
Test 2 groups of each chick embryo allantoic cavities and be inoculated with yellow bark of ash sample 2 stoste 0.2mL, viral dilution liquid 0.1mL simultaneously.
Test the ACV 0.2mL that 3 groups of each chick embryo allantoic cavities are inoculated with 62.5mg/mL simultaneously, viral dilution liquid
0.1mL。
Test 4 groups of each chick embryo allantoic cavities and be inoculated with bark of ash parenteral solution 0.2mL, viral dilution liquid 0.1mL simultaneously.
Each chick embryo allantoic cavity of positive controls is inoculated with physiological saline 0.2mL, viral 0.1mL simultaneously.
Blank control group not virus inoculation, is not administered.
Above-mentioned chicken embryo continues hatching in 38 DEG C of insulating boxs, daily according to egg 2~3 times, discards dead germ in 24h, collect 24~
The allantoic fluid of 72h dead germs and 72h work embryos, Cord blood is standby.With the virus titer of blood clotting (HA) experiment detection chick embryo allantoic liquid.
(3) influence that yellow bark of ash is bred to newcastle disease virus, the results are shown in Table 3.
The inhibitory action measurement result that the yellow bark of ash of table 3 is bred to newcastle disease virus
| Packet | 24~72h death embryo numbers | 72h work embryo numbers | HA potency |
| The yellow stoste of bark of ash sample 1 | 2** | 9** | 0** |
| The yellow stoste of bark of ash sample 2 | 3** | 8** | 0** |
| ACV group | 11 | 0 | 0** |
| Bark of ash control group | 11 | 0 | 5log2 |
| Positive controls | 11 | 0 | 8log2 |
| Blank control group | 0 | 11 | 0 |
Compare with positive controls：**P<0.01
2nd, therapeutic test of the present invention to Chickens ewcastle disease
1st, experimental animal：This experiment 35 age in days AA broiler chicken 200, is randomly divided into 10 groups, every group 20, the Ji Huang Qin
(being prepared by the embodiment 3) prevention group of Macrophylla sample 1 and treatment group, yellow (being prepared by the embodiment 4) prevention group of bark of ash sample 2 and treatment
Group, bark of ash (being prepared by embodiment 11) prevention group and treatment group, Western medicine prevention group and treatment group, infect control group, blank
Group.
2nd, newcastle disease strain is provided by our unit laboratory, and the HA potency of chick embryo allantoic liquid is 8log2。
3rd, test method：
(1) allantoic fluid minimum lethal dose is first determined, the minimum lethal dose of allantoic fluid is 150 times of dilutions, every chicken after measured
Allantoic fluid 0.2mL after collunarium and eye droppings dilution.
(2) the chicken not medication of operating space control group, is not inoculated with allantoic fluid, and remaining 9 groups chicken is every in the same time
Allantoic fluid 0.2mL after the dilution of collunarium eye droppings.
(3) administrated method starts with yellow bark of ash sample with the prevention group of curative effect Huang bark of ash sample 1 while allantoic fluid is inoculated with
1 is oral, and every each 0.3mL of chicken, daily medication 2 times is used in conjunction 4d.The yellow treatment group of bark of ash sample 1 (goes out after inoculation allantoic fluid 4d
Existing symptom) medication, every each 0.3mL of chicken, daily medication 2 times is used in conjunction 4d.The yellow prevention group of bark of ash sample 2 is in inoculation allantoic fluid
While, oral with yellow bark of ash sample 2, every each 0.3mL of chicken, daily medication 2 times is used in conjunction 4d；The yellow treatment group of bark of ash sample 2
The medication that (symptom occurs) after inoculation allantoic fluid 4d, every each 0.3mL of chicken, daily medication 2 times is used in conjunction 4d.Bark of ash oral liquid
Prevention group starts with bark of ash oral liquid orally while allantoic fluid is inoculated with, and every each 1mL of chicken, daily medication 2 times is used in conjunction
4d.Medication that bark of ash oral liquid treatment group (symptom occurs) after inoculation allantoic fluid 4d, every each 1mL of chicken, daily medication 2 times,
It is used in conjunction 4d.While allantoic fluid is inoculated with, the ACV with 62.5mg/mL is oral, every chicken 1mL for ACV prevention group,
2 times a day, is used in conjunction 4d.(there is symptom) after inoculation allantoic fluid 4d in Aciclovir Treatment group, with the ACV of 62.5mg/mL
Drug therapy, every each 1mL of chicken is oral, daily 2 times, is used in conjunction 4d.The chicken inoculation allantoic fluid of control group is infected, without any
Medicine, the results are shown in Table 4.
The newcastle disease of table 4 is prevented and treatment results unit：%
3rd, clinical observation of the present invention to newcastle disease treatment
A kind of acute highly contagious disease that newcastle disease is caused by NDV, the chicken of various ages in days can send out
Disease, often passes through in septicemia, is mainly characterized by expiratory dyspnea, diarrhea, nerve disorder, mucous membrane and serous coat bleeding, the death rate
Height, can cause very big economic loss.(made by embodiment 4 with yellow bark of ash sample 1 (being prepared by embodiment 3) and yellow bark of ash sample 2
It is standby), every each oral 0.3mL of chicken, daily medication twice, is used in conjunction 4 days.Drug therapy is carried out to morbidity chicken in 4, Guangxi county
Experiment, the results are shown in Table 5, table 6.
The yellow bark of ash sample 1 of table 5 is to newcastle disease clinical efficacy result unit：%
The yellow bark of ash sample 2 of table 6 is to newcastle disease clinical efficacy result unit：%
It can be seen that, the example of drug therapy newcastle disease more than 1,000 made by the present invention obtains good therapeutic effect, general treatment 2d
Stop afterwards dead, can cure after 3~4d, cure it is latter as do not recur, show that present invention treatment newcastle disease has curative effect very high.
4th, the present invention is to swine fever and the clinical treatment outcome of Porcine circovirus desease
There is 45 age in days piglet 148 on November 15th, 2013, Guangxi Zhongshan County scale pig farm, spiritual depressed, food occurs
It is intended to go down or useless exhausted.June 16, body temperature rises to 40.8 DEG C or so, and whole skin has blutpunkte, diarrhoea, inguinal lymph nodes
Enlargement.Cut open inspection 2, cut open inspection change：Larynx, bladder, kidney have blutpunkte, and lymph node changes in marble sample, and large intestine has necrosis
Stove.The detection of whole blood colloidal gold strip is adopted, swine fever and pig circular ring virus are the positive, are diagnosed as CSFV and pig circular ring virus 2
Malicious mixed infection.Immediately with medication therapy groups of the present invention 1 (being prepared according to the method for embodiment 5), medication therapy groups of the present invention 2
(being prepared according to the method for embodiment 6) and medication therapy groups of the present invention 3 (being prepared according to the method for embodiment 7) are treated, and
It is control drug with astragalus polyose, treats 4 days altogether, daily medication 2 times, treatment results is shown in Table 7, table 8, table 9.
The swine fever of table 7 and pig circular ring virus mixed infection clinical efficacy result unit：Head %
The swine fever of table 8 and pig circular ring virus mixed infection clinical efficacy result unit：Head %
The swine fever of table 9 and pig circular ring virus mixed infection clinical efficacy result unit：Head %
Seen by this clinical practice result, injections treatment swine fever of the present invention, Porcine circovirus desease, curative effect is than yellow
Astragalus polysaccharides effect is obvious.Show Chinese medicine preparation of the present invention, treatment pig virus infectious disease has significant curative effect.
7th, safety evaluatio
The oral liquid prepared with the embodiment of the present invention 3, the median lethal dose of Mouse oral is 15.12 ± 0.79g/kg.Often
Day gives mouse gavaging oral liquid 30g/kg of the present invention, takes medicine continuously 3d, there are no anomaly.Oral liquid 18g/kg of the present invention is to rat
Gavage, continuous 21 days, also finds no histological change
Specific embodiment
The present invention is further described below by way of specific embodiment：
The preparation of the extract 1 of the present invention of embodiment 1
Yellow bark of ash 500g, after soaking 6h by 10 times of medicinal material weight, puts Decocting pot and endures 1h, leaches liquid, then dosing
10 times of decocting 1h of material weight, leach liquid, merge liquid twice, and dehydration is concentrated into paste, and 60 DEG C of low temperature dryings there are
55g extracts.
The preparation of the extract 2 of the present invention of embodiment 2
Yellow bark of ash 500g is taken, is crushed, with 10 times of amounts of yellow bark of ash powder weight, mass percentage concentration is 85% ethanol immersion 4
After hour, diacolation reclaims ethanol, is concentrated into paste, and 60 DEG C of low temperature dryings there are 45g extracts.
The preparation of the oral liquid 1 of the present invention of embodiment 3
Yellow bark of ash 500g is taken, 6h is soaked by 8 times of medicinal material weight, put Decocting pot decocting 2h, leach liquid, then dosing
8 times of decocting 2h of material weight, leach liquid, merge liquid twice, are concentrated into 500mL, bottle, sealing, sterilizing.
The preparation of the oral liquid 2 of the present invention of embodiment 4
Yellow bark of ash 500g is taken, after being soaked 4 hours in 10 times of 80% ethanol of amount of yellow gentiana macrophylla medicine weight, diacolation reclaims second
Alcohol, is concentrated into 500mL, bottling, sealing, sterilizing.
The preparation of the injection 1 of the present invention of embodiment 5
Yellow bark of ash 1000g is taken, 6h is soaked by 12 times of medicinal material weight, put Decocting pot and endure 1h, leach liquid, then Jia 10
Times decocting 1h, leaches liquid, merges liquid twice, and dehydration is concentrated into thick shape, and the ethanol for adding mass percentage concentration to be 95% makes
Up to 60%, after placing 24h, suction filtration reclaims ethanol to alcohol content.Filtrate adds the ethanol that mass percentage concentration is 95%, makes to contain
Up to 70%, after placing 24h, suction filtration reclaims ethanol to alcohol amount.By filtrate plus distilled water to 800mL.8 grams of activated carbon is added, is boiled
Constant temperature 30min, filtrate adds distilled water to 1000mL, is heated to 80 DEG C, adds 20mL phenmethylols, and suction filtration adjusts pH to clear and bright repeatedly
To 7.0, embedding, sterilize 30min, standby.
The preparation of the injection 2 of the present invention of embodiment 6
Yellow bark of ash 1000g is taken, is crushed, be dissolved in 10 times of yellow gentiana macrophylla medicine weight amount, during concentration is 90% ethanol, after immersion 4h
Filtering, residue soaks 4h and filters with 90% ethanol again, merges filtrate twice, reclaims ethanol extremely without alcohol taste, by concentration of liquid medicine extremely
800mL, adds 8 grams of activated carbons, boils constant temperature 30min, and suction filtration, filtrate adds distilled water to 1000mL, is heated to 80 DEG C, adds
20mL phenmethylols, suction filtration is to clear and bright, embedding repeatedly, and sterilize 30min, standby.
The preparation of the injection 3 of the present invention of embodiment 7
Yellow bark of ash 1000g is taken, is crushed, be dissolved in 8 times of yellow gentiana macrophylla medicine weight amount, during concentration is 80% methyl alcohol, after immersion 5h
Filtering, residue soaks 5h and filters with 80% methyl alcohol again, merges filtrate twice, reclaims methyl alcohol extremely without alcohol taste, by concentration of liquid medicine extremely
800mL, adds 8 grams of activated carbons, boils constant temperature 30min, and suction filtration, filtrate adds distilled water to 1000mL, is heated to 80 DEG C, adds
20mL phenmethylols, suction filtration is to clear and bright, embedding repeatedly, and sterilize 30min, standby.
The preparation of the extract 3 of the present invention of embodiment 8
Yellow bark of ash 500g is taken, is crushed, with 10 times of amounts of yellow bark of ash powder weight, mass percentage concentration is 75% ethanol immersion 4
After hour, diacolation reclaims ethanol, is concentrated into paste, and 60 DEG C of low temperature dryings there are 43g extracts.
The preparation of the extract 4 of the present invention of embodiment 9
Yellow bark of ash 500g is taken, is crushed, with 10 times of amounts of yellow bark of ash powder weight, mass percentage concentration is 85% methyl alcohol immersion 4
After hour, diacolation reclaims methyl alcohol, is concentrated into paste, and 60 DEG C of low temperature dryings there are 40g extracts.
The preparation of the Tablets of embodiment 10
The yellow Radix Gentianae Macrophyllae extract plus dextrin that will be prepared according to the method for embodiment 1, mixed pelletization, 60 DEG C of drying cross 20
Mesh sieve whole grain, compressing tablet.
The preparation of the bark of ash oral liquid of embodiment 11
Bark of ash 500g is taken, 8h is soaked by 8 times of medicinal material weight, put Decocting pot decocting 2h, leach liquid, then dosing material
5 times of decocting 2h of weight, leach liquid, merge liquid twice, are concentrated into 500mL, bottle, sealing, sterilizing.
The preparation of the bark of ash injection of embodiment 12
Bark of ash 1000g is taken, is crushed, be dissolved in 8 times of gentiana macrophylla medicine weight amount, during concentration is 80% ethanol, filtered after immersion 5h,
Residue soaks 5h and filters with 80% ethanol again, merges filtrate twice, reclaims ethanol to without alcohol taste, by concentration of liquid medicine to 800mL, plus
Enter 8 grams of activated carbons, boil constant temperature 30min, suction filtration, filtrate adds distilled water to 1000mL, be heated to 80 DEG C, add 20mL benzene first
Alcohol, suction filtration is to clear and bright, embedding repeatedly, and sterilize 30min, standby.
Claims (9)
1. application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease.
2. the application according to claim, it is characterised in that described livestock and poultry virus sexually transmitted disease is newcastle disease or swine disease
Toxoinfection disease.
3. application according to claim 1, it is characterised in that described pig virus infectious disease is Porcine circovirus desease, pig
Pest or swine fever and pig circular ring virus mixed infection.
4. application according to claim 1, it is characterised in that described yellow bark of ash includes that yellow bark of ash raw medicinal herbs, yellow bark of ash are carried
Take thing, yellow bark of ash processed product or the preparation with yellow bark of ash as active component.
5. application according to claim 4, it is characterised in that described extract is water or extractive with organic solvent.
6. application according to claim 5, it is characterised in that described organic solvent is ethanol or methyl alcohol.
7. application according to claim 5, it is characterised in that described organic solvent is that mass percent concentration is 70%
~90% ethanol or mass percent concentration are 75%~85% methyl alcohol.
8. application according to claim 4, it is characterised in that described preparation is that yellow bark of ash raw medicinal herbs or its extract are straight
Crushing is connect to be made powder or add pharmaceutically acceptable auxiliary material to be made oral formulations or injection.
9. application according to claim 8, it is characterised in that the oral formulations are mixture, tablet or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710236683.4A CN106924337A (en) | 2017-04-12 | 2017-04-12 | Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710236683.4A CN106924337A (en) | 2017-04-12 | 2017-04-12 | Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924337A true CN106924337A (en) | 2017-07-07 |
Family
ID=59436605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710236683.4A Pending CN106924337A (en) | 2017-04-12 | 2017-04-12 | Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924337A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001028584A1 (en) * | 1999-10-15 | 2001-04-26 | The University Of Sydney | Treatment of respiratory diseases and infections |
-
2017
- 2017-04-12 CN CN201710236683.4A patent/CN106924337A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001028584A1 (en) * | 1999-10-15 | 2001-04-26 | The University Of Sydney | Treatment of respiratory diseases and infections |
Non-Patent Citations (5)
| Title |
|---|
| 冯翠兰: "《现代养猪实用技术》", 31 August 2011, 广东科技出版社 * |
| 刘焕奇: "《兽医学》", 30 June 2013, 中国海洋大学出版社 * |
| 周广生: "中药"金不换"注射液在鸡胚中对鸡新城疫病毒的抑制试验", 《动物医学进展》 * |
| 王金玉: "猪瘟的免疫程序与免疫防治对策", 《乡村科技》 * |
| 谢玉: "猪圆环病毒病的防治技术", 《中国畜牧兽医文摘》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1330330C (en) | Antivirus medicinal composition, preparation method and use | |
| CN101804162A (en) | Anti-newcastle disease virus Chinese medicinal composition and preparation method thereof | |
| CN101259160B (en) | Compound preparations for treating birdsvirosis and preparation thereof | |
| CN100586454C (en) | Chinese medicine composition for birds, preparing method and application of the same | |
| CN102872307A (en) | Traditional Chinese medicine oral liquid for preventing and treating virus diseases of poultry and method for preparing traditional Chinese medicine oral liquid | |
| CN107661416A (en) | A kind of traditional Chinese medicine extraction compound pharmaceutical for preventing and treating livestock and birds respiratory disease | |
| CN102670694A (en) | Traditional Chinese medicine combination for treating porcine pseudorabies and preparation method and application thereof | |
| CN103239518B (en) | Traditional Chinese medicine composition for treating avian influenza | |
| CN104840591B (en) | A kind of Chinese medicine composition for having effects that to prevent ewcastle disease | |
| CN104585511A (en) | Feed additive for controlling poultry influenza plague | |
| CN105726742B (en) | A kind of anti-newcastle disease virus disease and the herbal medicine of bird flu and preparation method thereof | |
| CN101982188B (en) | Application of Tangut dragonhead in preparation of drugs for treating livestock and poultry viral infectious diseases | |
| CN106924337A (en) | Application of the yellow bark of ash in the medicine for preparing treatment livestock and poultry virus sexually transmitted disease | |
| CN102813721A (en) | Pharmaceutical composition for livestock heat clearing and livestock detoxifying and preparation method thereof | |
| CN101797345B (en) | Traditional Chinese medicine composition for preventing and treating viral diseases of poultry and preparation method | |
| CN109758487A (en) | Tuber fern prevents and treats porcine pseudorabies and circovirus mixed infection and the application of goose paramyxovirus | |
| CN101549011B (en) | Application of tassel herbamoslae in preparing medicaments for treating infectious diseases of beasts and birds | |
| CN105168817B (en) | A kind of Chinese medicine composition for preventing Duckling flavivirus disease | |
| CN105998319A (en) | Application of Chinese soapberry fruits to preparing of medicine for treating livestock-poultry viral infectious diseases | |
| CN102266383B (en) | Application of Mesona chinensis Benth in preparing medicines for treating viral infectious diseases in livestock and poultry | |
| CN102283872B (en) | Application of henslowia in preparation of medicaments for treating viral infectious diseases of livestock and poultry | |
| CN102895422B (en) | Application of tetrastlgma hemsleyanum in preparing drug for treating livestock viral infectious diseases | |
| CN107669957B (en) | Compound traditional Chinese medicine extract for preventing and treating animal echinococcosis and application thereof | |
| CN102145032B (en) | Application of plumeria acutifolia for preparing medicine for treating poultry viral infection | |
| CN110269873A (en) | Hygrometric boea herb is used to prevent and treat the purposes of H1N1 swine influenza |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170707 |
|
| WD01 | Invention patent application deemed withdrawn after publication |